Lincoln Pharmaceuticals Stock Falls to 52-Week Low of Rs.481

Stock Price Movement and Market Context

On 8 December 2025, Lincoln Pharmaceuticals’ share price touched Rs.481, the lowest level recorded in the past year. This new low comes after three consecutive days of declines, during which the stock has recorded a cumulative return of -1.69%. The day’s movement was in line with the sector’s overall performance, with a marginal day change of -0.12%.

Despite the broader market’s resilience, the Sensex experienced a negative session, closing at 85,395.97 points, down by 228.87 points or 0.37%. Notably, the Sensex remains close to its 52-week high of 86,159.02, trading just 0.89% below that peak. The index continues to trade above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a generally bullish trend for the broader market.

In contrast, Lincoln Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum for the stock relative to its recent trading history.

Long-Term Performance and Financial Metrics

Over the past year, Lincoln Pharmaceuticals has recorded a total return of -46.31%, a stark contrast to the Sensex’s positive return of 4.52% during the same period. This underperformance extends beyond the last 12 months, with the stock also lagging behind the BSE500 index over the last three years, one year, and three months.

The stock’s 52-week high was Rs.975, indicating a substantial decline of over 50% from that peak to the current 52-week low. This wide price range highlights the volatility and challenges faced by the company in recent times.

Recent Financial Results and Profitability

Lincoln Pharmaceuticals’ recent quarterly results indicate subdued profitability. The Profit After Tax (PAT) for the quarter stood at Rs.19.98 crores, reflecting a decline of 24.1% compared to the previous corresponding period. Similarly, the Profit Before Tax excluding other income (PBT less OI) was Rs.21.58 crores, down by 12.98%.

The company’s Return on Capital Employed (ROCE) for the half-year period is reported at 15.46%, which is the lowest level recorded in recent times. This metric is a key indicator of how efficiently the company is utilising its capital base to generate earnings.

Over the last five years, Lincoln Pharmaceuticals’ net sales have grown at an annual rate of 9.21%, while operating profit has expanded at a rate of 5.37%. These figures suggest moderate growth in revenue and earnings, but the pace has not been robust enough to support a stronger stock performance.

Shareholding and Market Perception

Despite Lincoln Pharmaceuticals’ size within the Pharmaceuticals & Biotechnology sector, domestic mutual funds hold no stake in the company. Given that mutual funds typically conduct detailed research and due diligence, their absence from the shareholding pattern may reflect a cautious stance towards the stock’s current valuation or business outlook.

The company’s debt profile remains conservative, with an average Debt to Equity ratio of zero, indicating no reliance on borrowed funds for its capital structure. This low leverage is a positive aspect in terms of financial stability.

Lincoln Pharmaceuticals’ Return on Equity (ROE) stands at 11.2%, and the stock trades at a Price to Book Value of 1.4. These valuation metrics suggest that the stock is priced fairly relative to its book value and profitability, especially when compared to peers in the sector.

Profit Trends and Valuation Context

Over the past year, Lincoln Pharmaceuticals’ profits have declined by 17.2%, a factor contributing to the stock’s subdued performance. While the company maintains an attractive valuation relative to its peers’ historical averages, the downward trend in earnings has weighed on investor sentiment.

The stock’s performance relative to the broader market and sector indices highlights the challenges faced by Lincoln Pharmaceuticals in maintaining growth momentum and profitability in a competitive industry environment.

Summary of Key Metrics

To summarise, Lincoln Pharmaceuticals’ stock has reached Rs.481, its lowest level in 52 weeks, following a series of declines and underperformance relative to the Sensex and sector benchmarks. The company’s financial results show a contraction in profits and modest growth in sales over the medium term. Its valuation metrics remain reasonable, supported by low debt and a fair Price to Book ratio, but recent profit declines have influenced market performance.

These factors collectively provide a comprehensive picture of the stock’s current standing within the Pharmaceuticals & Biotechnology sector.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →